Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
5.52
+0.01 (0.18%)
Apr 30, 2026, 4:00 PM EDT - Market closed
Company Description
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.
It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.
The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Kalaris Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Andrew Oxtoby |
Contact Details
Address: 400 Connell Drive, Suite 5500 Berkeley Heights, New Jersey 07922 United States | |
| Phone | 650-249-2727 |
| Website | kalaristx.com |
Stock Details
| Ticker Symbol | KLRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001754068 |
| CUSIP Number | 482929106 |
| ISIN Number | US4829291065 |
| Employer ID | 83-1971007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew Oxtoby | President, Chief Executive Officer and Director |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director and Co-Founder |
| Dr. Michael Philip Dybbs Ph.D. | Director and Co-Founder |
| Dr. Napoleone Ferrara M.D. | Independent Director and Co-Founder |
| Brett R. Hagen | Chief Accounting Officer and Principal Accounting and Financial Officer |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer |
| Kristine Curtiss | Senior Vice President of Clinical |
| Dr. Jill E. Porter Ph.D. | Senior Vice President of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 13, 2026 | EFFECT | Notice of Effectiveness |
| Apr 13, 2026 | EFFECT | Notice of Effectiveness |
| Apr 13, 2026 | 424B3 | Prospectus |
| Apr 13, 2026 | 424B3 | Prospectus |
| Apr 10, 2026 | 8-K | Current Report |
| Apr 3, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 3, 2026 | S-3 | Registration statement under Securities Act of 1933 |